AMERISAFE's stock has seen its fair value price target hold steady at $50.33, supported by consistent revenue growth estimates and a stable outlook from analysts. However, the discount rate has inched higher, reflecting heightened caution amid ongoing sector pressures and mixed sentiment from market observers. Stay tuned to discover how you can stay ahead of shifts in the evolving AMERISAFE narrative as market conditions change.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value AMERISAFE.

???? Bullish Takeaways

Citizens JMP maintains an Outperform rating on AMERISAFE, reflecting a continued positive bias toward the company’s execution and growth prospects, even as the price target has been reduced to $60 from $65.

The firm anticipates that lighter than typical catastrophe losses and modest tailwinds from mark-to-market book values could support sector results, potentially benefiting AMERISAFE’s fundamentals.

Analysts acknowledge AMERISAFE’s generally stable profitability and relatively steady outlook within the property and casualty insurance space.

Key reservations among bullish analysts include ongoing concerns about casualty loss reserves and the competitive pricing environment.

???? Bearish Takeaways

Truist has lowered its price target on AMERISAFE to $45 from $50 while maintaining a Hold rating, citing valuation pressures throughout the broader property and casualty industry.

Truist’s Hold stance highlights a view that the stock is fairly valued at current levels, with limited near-term upside given the company’s outlook for stable, but not accelerating, profitability.

Both Truist and Citizens JMP echo concerns regarding ongoing market pressures, indicating that upside in AMERISAFE shares may already be reflected in its current valuation.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Truist has lowered its price target on AMERISAFE shares to $45 from $50 while maintaining a Hold rating. The firm highlights ongoing valuation pressures in the property and casualty insurance sector and notes the company’s stable but unaccelerated profitability.

Chief Financial Officer Anastasios Omiridis has informed AMERISAFE of his intention to resign effective November 30, 2025. During the search for a new CFO, President and CEO G. Janelle Frost will take on the duties of principal financial officer.

AMERISAFE executed two share buyback tranches in the third quarter of 2025, repurchasing a combined total of 30,860 shares for $1.3 million.

The Board of Directors has announced a special cash dividend of $1.00 per share, scheduled for payment on December 12, 2025.

Fair Value has remained unchanged and is holding steady at $50.33.

The Discount Rate has risen slightly, increasing from 6.78% to 6.96%.

Revenue Growth projections are essentially flat, with estimates stable at approximately 4.61%.

Net Profit Margin is unchanged and remains near 9.94%.

The Future P/E ratio has increased marginally from 31.29x to 31.44x.

Narratives are a smarter, easier way to invest. Investors connect the story behind a company to its financial numbers and estimate fair value. By weaving together news, forecasts, and personal insights, Narratives link the latest company developments to revenue, earnings, and margin estimates, which can make buy or sell decisions clearer. Available within the Simply Wall St Community, Narratives are continuously updated and help millions of investors stay informed as new information emerges.

See the latest perspective and follow the original AMERISAFE Narrative to keep your finger on the pulse of every key shift:

Read the AMSF Narrative for insights on how profit resilience and sector trends could impact share performance.

Track catalysts such as robust policy growth and technology investment that may drive revenue expansion and margin improvement.

Stay alert to potential risks, including pricing pressure, rising costs, and industry headwinds, and how these affect AMERISAFE’s fair value outlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AMSF.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com